Fast, Accessible, Genetics-Focused Liquid Biopsy
Ultra-sensitive multiplex mutation detection on existing PCR infrastructure.
Enabling Faster, affordable and accessible cancer testing
The Actionability Gap in Cancer Care
Cancer treatment increasingly depends on timely molecular information. Yet current liquid biopsy approaches are often too costly, too centralized, or too limited for frequent use throughout the patient journey.
Why Infiniplex
Ultra-Sensitive
Mutation detection down to 0.01% VAF
Multiplex
Multiple actionable mutations in a single PCR workflow
Accessible
Designed for standard PCR infrastructure available worldwide
Actionable Molecular Insights. Within Hours
Rapid, mutation-specific insights designed to support precision oncology decisions
In a Nutshell
Infiniplex is a deep-tech precision oncology company developing advanced liquid biopsy solutions for precision oncology. Its core platform, InfiniplexDX, is designed to enable rapid, sensitive and accessible mutation detection.
By combining proprietary, ultra-high-performance primer design with widely available PCR infrastructure, InfiniplexDX enables rapid, highly sensitive and specific detection of target mutations in blood and urine samples.
These molecular insights can support better-informed treatment decisions while reducing reliance on invasive tissue biopsies and the associated risks, limitations and technical challenges.
Our multidisciplinary team combines scientific excellence, clinical relevance and a shared commitment to making precision oncology more accessible.
Advanced Mutation Detection on Standard PCR
InfiniplexDx combines proprietary molecular-switch chemistry with software-supported signal interpretation to enable sensitive, specific, and multiplex detection of clinically relevant cancer mutations in liquid biopsy samples.
The platform is designed to run on standard PCR instruments, enabling faster and more accessible molecular testing without the need for sequencing infrastructure.
How the Technology Works
layer 1:
Molecular-Switch Chemistry
Proprietary PCR primers engineered with thermodynamic precision. Our ultra-high-specificity primer architecture maximizes thermodynamic discrimination to selectively amplify rare mutant alleles while suppressing wild-type amplification, enabling detection of a single mutant molecule among 1,000–10,000 wild-type molecules.
Layer 2:
Algorithmic Deciphering
Advanced computational algorithms analyze complex multiplex PCR data – deconvolving overlapping fluorescent signatures to detect single-digit mutant molecules amid wild-type excess. Software-supported signal processing that extracts meaning from the noise.
Five Priority Clinical Indications
Infiniplex is advancing InfiniplexDx across five priority clinical indications:
NMIBC -non-muscle-invasive bladder cancer, MDS -myelodysplastic syndromes, PDAC-pancreatic ductal adenocarcinoma, CRC-colorectal cancer, and NSCLC – non-small cell lung cancer.
These indications were selected based on clinical need, mutation-panel relevance, testing frequency, and their potential to benefit from faster, more accessible molecular insights.
Market Opportunity Across Five Priority Clinical Indications
Worldwide TAM by indication
The five clinical indications currently targeted by Infiniplex represent an estimated worldwide total addressable market of €18.4B.
Share of Worldwide TAM
Our Team
A multidisciplinary team combining molecular diagnostics, clinical expertise, product development, and business leadership.
Alon Shalev
CEO
Leads Infiniplex’s strategy, business development, partnerships, and commercialization
Zeev Russak
CTO
Leads the development of Infiniplex’s core molecular technology and platform innovation
Dr. Asa Eitan
CSO
Drives scientific translation, bringing expertise in nanotechnology and molecular biology to clinically relevant applications.
Dr. Ortal Cohen
VP R&D
Leads Infiniplex’s research and development activities, overseeing molecular technology development, platform innovation, and product development.
Efrat Herscovitch
CFO
Leads Infiniplex’s financial strategy and operations, drawing on over 20 years of experience with startups and technology incubators.
Yael Furman
VP Clinical, Regulatory & QA
Guides Infiniplex’s clinical, regulatory, and quality activities, supporting the translation of the platform into validated clinical applications.
Shira Sagee
VP Grants & HR
Shapes Infiniplex’s grant strategy and funding activities, while supporting human resources, organizational development, and company growth
Adi Telem
Researcher
Supports molecular assay development through experimental execution, optimization, data analysis, and validation of new workflows.
Inbal Itzhak
Senior Researcher
Leads molecular assay development, provides scientific guidance to the R&D team, and supports experimental design and data analysis.
Sagi Shaked
Bioinformatician
Develops bioinformatics pipelines and analytical tools to support assay development, data interpretation, and platform validation.
Yaely Segman
Softwear Developer
Develops software and analytical tools that support data processing, assay interpretation, and the continued development of the Infiniplex platform.
Shani Lavi
Researcher
Supports day-to-day laboratory activities, including molecular testing, sample preparation, and accurate execution of experimental procedures.
